Maternal exposure to the synthetic cannabinoid HU-210: effects on the endocrine and immune systems of the adult male offspring.
Natural and synthetic cannabinoid receptor agonists have been described to exert profound effects on both the neuroendocrine integration and the functional responses of the immune system. In the present study, Wistar rats were exposed to the highly potent cannabinoid agonist HU-210 (1, 5 and 25 microg/kg) during gestation and lactation and the ensuing effects on several endocrine and immune parameters of the adult male offspring were analyzed. Perinatal exposure to HU-210 partially affected the distribution of lymphocyte subpopulations in the spleen and peripheral blood. The major changes observed occur after maternal exposure to the 25 microg/kg dose of HU-210. There was a reduction in the T-helper subpopulation in the spleen and a dose-related decrease in the rate of T(helper)/T(cytotoxic) in peripheral blood lymphocytes. Concanavalin-A and lipopolysaccharide-induced proliferation were normal in all the groups tested. In the same animals, perinatal exposure to HU-210 did not affect basal levels of growth hormone, IGF-1, prolactin, or follicle-stimulating hormone. Basal values of luteinizing hormone were elevated in animals given the 1 microg/kg dose of HU-210. Corticosterone levels were reduced in the animals exposed to the higher dose of HU-210 during gestation and lactation. These animals exhibited a decreased responsiveness of the hypothalamo-pituitary-adrenal (HPA) axis to the stimulation with a single injection of HU-210 (20 microg/kg, i.v.) at adult ages, which may reflect the onset of long-lasting tolerance to the HPA-activating properties of cannabinoids. The opposite pattern of response was found in the animals given the 1 microg/kg dose, in which a sensitization of the corticosterone response to acute HU-210 was observed. The present work reveals that maternal exposure to cannabinoids results in minor changes in the development of the immune system, but may induce long-lasting alterations in the functional status of the HPA axis.
del Arco
I
I
Instituto Complutense de Drogodependencias (Departamento de Psicobiología, Facultad de Psicología), Madrid, Spain.
Muñoz
R
R
Rodríguez De Fonseca
F
F
Escudero
L
L
Martín-Calderón
J L
JL
Navarro
M
M
Villanúa
M A
MA
D000284:Administration, Oral; D000367:Age Factors; D000818:Animals; D003345:Corticosterone / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004326:Drinking / Q000187:drug effects; D013759:Dronabinol / Q000031:analogs & derivatives* / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D013006:Growth Hormone / Q000097:blood; D007107:Immune System / Q000187:drug effects* / Q000254:growth & development; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D007774:Lactation / Q000187:drug effects; D016131:Lymphocyte Subsets / Q000187:drug effects; D008297:Male; D015213:Neuroimmunomodulation / Q000187:drug effects; D009490:Neurosecretory Systems / Q000187:drug effects* / Q000254:growth & development; D009929:Organ Size; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D011388:Prolactin / Q000097:blood; D051381:Rats; D017208:Rats, Wistar; D013154:Spleen / Q000276:immunology; D013950:Thymus Gland / Q000276:immunology; D015430:Weight Gain / Q000187:drug effects
D018691:Excitatory Amino Acid Antagonists; D007334:Insulin-Like Growth Factor I; D013759:Dronabinol; D011388:Prolactin; D005640:Follicle Stimulating Hormone; D013006:Growth Hormone; C062018:HU 211; D003345:Corticosterone